109P Patient-reported outcomes with acasunlimab monotherapy and in combination with pembrolizumab: Results from a phase II study of PD-L1+ mNSCLC

Acasunlimab (ACA, DuoBody®-PD-L1x4-1BB) monotherapy and in combination with pembrolizumab (PEM; Q3W/Q6W) was evaluated in a Ph 2 trial of patients (pts) with PD-L1+ mNSCLC who progressed after ≥1 prior SOC treatment including PD-L1 inhibitors (NCT05117242). ACA+PEM Q6W showed promising OS, durable benefit, and a manageable safety profile. Exploratory analyses were conducted to assess patient-reported outcomes (PROs) and HRQoL from primary analysis of the Ph 2 trial at data cutoff (12/02/2024).